We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Realm Therapeutics

20 Feb 2019 10:33

RNS Number : 6181Q
Nplus1 Singer Capital Markets Ltd
20 February 2019
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Nplus1 Singer Capital Markets Limited

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Realm Therapeutics Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Realm Therapeutics Plc

(d) Date dealing undertaken:

19 February 2019

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

If YES, specify which:

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

Ord 10p

 

 

Purchase

 

4,872,800

 

8p

 

6.5p

 

Ord 10p

 

 

Sale

 

4,540,124

 

7.989p

 

6.5p

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

20 February 2019

Contact name:

Damian Fernandez

Telephone number:

020 7496 3094

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERBGGDDBXDBGCG
Date   Source Headline
31st Jan 20139:00 amRNSTotal Voting Rights
17th Jan 20135:22 pmRNSHolding(s) in Company
17th Jan 20134:44 pmRNSHolding(s) in Company
17th Jan 20134:42 pmRNSHolding(s) in Company
17th Jan 20134:37 pmRNSHolding(s) in Company
17th Jan 20134:33 pmRNSHolding(s) in Company
17th Jan 20134:25 pmRNSHolding(s) in Company
17th Jan 20134:24 pmRNSHolding(s) in Company
10th Jan 20134:53 pmRNSBoard Changes
10th Jan 20134:36 pmRNSResult of General Meeting
19th Dec 20123:25 pmRNSPublication of Prospectus
19th Dec 20127:00 amRNSRestructuring of Loan Notes and Placing
19th Nov 20127:00 amRNSInterim Management Statement
15th Nov 20127:00 amRNSLohas partnering agreement
9th Oct 20127:00 amRNSPuriCore Signs Two Major US Deals
3rd Oct 20127:00 amRNSPositive Results from ActiVita Research
15th Aug 20122:34 pmRNSBlocklisting Application
13th Aug 20121:07 pmRNSBlocklisting Interim Review
8th Aug 20121:53 pmRNSNotification of Executive Chairman's Option Grant
6th Aug 20127:00 amRNSHalf Yearly Report
26th Jul 20127:00 amRNSNotice of Results
26th Jun 201211:54 amRNSHolding(s) in Company
25th Jun 20129:00 amRNSDirector's Dealing
12th Jun 201211:36 amRNSResult of AGM
30th May 20127:00 amRNSBoard and Organisational Changes
21st May 20127:00 amRNSAnnual Information Update
30th Apr 20127:00 amRNSDirector Dealing and Share Option Grant
26th Apr 20127:00 amRNSInterim Management Statement
26th Apr 20127:00 amRNSFinal Results
25th Apr 20129:13 amRNSNotice of Results
29th Mar 20127:00 amRNSAppointment of New Chairman and Board Changes
13th Feb 20127:00 amRNSNotification of Director's Details
3rd Feb 20123:22 pmRNSDirectors dealings and share option grants
2nd Feb 20124:59 pmRNSBlocklisting Interim Review
1st Feb 20127:02 amRNSBBSRC Industrial Partner Award
1st Feb 20127:01 amRNSDirectorate Change
1st Feb 20127:00 amRNSPre-Close Trading Update
17th Jan 20127:00 amRNSPuriCore Aqualox EPA confirmation
3rd Jan 20127:00 amRNSRaises $3.5 Million Debt Facility
30th Dec 201110:45 amRNSTotal Voting Rights
19th Dec 20118:31 amRNSPuriCore Receives Two Major Contracts-Replacement
19th Dec 20117:54 amRNSPuriCore Receives Two Major Contracts
14th Dec 20117:00 amRNSAgriculture System Confirmed for Use by EPA
13th Dec 201112:44 pmRNSConvertible loan notes extension
18th Nov 20113:42 pmRNSInterim Management Statement
21st Oct 201111:57 amRNSConvertible Loan Notes Update
10th Oct 20118:21 amRNSHolding(s) in Company
22nd Sep 20114:35 pmRNSBoard and Organisational Changes
16th Sep 201111:19 amRNSNew $1.9million Debt Facility Agreed
5th Sep 20114:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.